Our team

The foundation upon which Pure Biologics is built comprises a group of exceptionally talented and energetic people who pursue every project and idea with passion. Our employees constitute a diverse and multidisciplinary team with extensive experience gained in domestic and international institutions alike. Each and every person who conceptualizes ideas and actively participates in implemented projects, ultimately determines the stability of the team and its full engagement in achieving set goals. Highly qualified staff, years of experience and a focus on effective cooperation enable us to reach successive milestones of R&D projects and to execute contracted research activities.

A scientist and entrepreneur. Filip acquired 15+ years of research experience, both in Poland and the USA, and over 10 years of experience in building start-ups. He received his Ph.D. in biochemistry from the University of Wroclaw in the Department of Protein Engineering. Next, he trained at the Institute of Molecular Medicine at Health Science Center in Houston, USA, in the laboratory of Nobel Prize laureate Professor Ferid Murad, where he investigated signaling proteins related to cardiovascular diseases. He obtained his executive MBA diploma at the Polish-American School of Business. Filip has broad experience in biotechnology-related businesses and is involved in many R&D projects associated with the development of new drugs and medical devices.

Dr. Filip Jeleń, MBA
Co-founder, President of the Board

Romuald Harwas graduated from the Faculty of Management at the Cracow University of Economics, majoring in accounting. He has several years of experience in finance. Romuald began his career from the position of financial analyst, was a management accountant, financial controller and then CFO and a board member of limited companies. In Poland, he worked at TVN, Luxmed and Synektik. Romuald spent more than six years abroad, working for among others, Australian syndicate Bradken. He has led transition processes of companies from NewConnect to the main market of the WSE and cooperated with various investment funds. Romuald is a specialist in management, accounting and economic analysis.

Romuald Harwas
Vice President of the Board, Chief Financial Officer

Pieter Spee graduated as medical biologist/biochemist and later specialized in immunology and oncology during his Ph.D. in Amsterdam. He worked at Novo Nordisk, where he went from a scientist dealing with cancer biology, angiogenesis, and immunology, through positions of principal investigator, project manager, up to Director of the NK cell biology department and then taking the position of Director and Scientific Director of the Department of Translational Immunology. At Novo Nordisk he took part in the development of Lirilumab and Monalizumab antibodies that are now in late-stage clinical development. He has served, among others, as CTO of FibroTX in Estonia (skin diagnostics), and CSO of Tikomed in Sweden (preclinical and clinical development of IBSOLVMIR for the improvement of pancreatic islet transplantation). He is a co-inventor of 7 patents in the field of antibodies and has authored almost 30 scientific publications.

Dr. Pieter Spee
Vice President of the Board, Chief Scientific Officer
Board of Directors information

Marta Wawrzyniak is a graduate of biotechnology at the University of Wrocław and Executive MBA studies at the Polish-American School of Business. At Pure Biologics, first she carried out projects in the areas of ​​antibody development, protein production and purification, and cell biology, before taking the role of project manager. Marta originated the PureSelect2 platform for antibody selection and has contributed to concepts driving the company’s drug development projects implemented by the company. Currently, Marta is the Operations Director. Being responsible for coordinating work of the company’s internal departments, she is involved in strategic areas of the company’s development, including raising funds for research projects, team building, internal improvement programs and the organization of an efficient work environment.

Marta Wawrzyniak, MBA
Chief Operating Officer

Przemysław Jurek graduated in biotechnology from the University of Wrocław. He also completed postgraduate studies in Industrial Pharmacy at the Jagiellonian University and Executive MBA studies at the Polish-American School of Business. Przemysław participated in a research internship in the group of Professor Kurt Gothelf at iNano at the University of Aarhus (Denmark). His main areas of expertise include aptamers, analysis of intermolecular interactions and early stages of drug development. He earned his Ph.D. on the basis of research and technology that he developed for Pure Biologics. Przemysław originated the platform for selection of chemically modified aptamers – PureApta. In the company, he is responsible for the research and development strategy, project portfolio management and coordinating the work of project managers.

Dr. Przemysław Jurek, MBA
Chief Business Officer

An expert in the field of capital transactions, commercial law, business transformation, finance and banking and management. As a long-term manager of the Lower Silesian Brokerage, he managed publicly traded private equity funds, handled business transformations, issuing projects and IPOs of technological companies listed in the ATS and on the WSE.

Andrzej Trznadel
Chairman of the Supervisory Board

Prof. dr hab. Julia Bar is a head of the Immunopathology and Molecular Biology Division of Wroclaw Medical University. She specializes in immuno-oncology, cancer biology and in regenerative medicine and tissue engineering experimental research. She conducts research on cancer cell resistance to chemotherapy and on stem cell-based biological implants. Her scientific achievements include two patents, several dozen research papers and almost two hundreds conference presentations.

Prof. Dr. hab. Julia Bar

Dr Tadeusz Wesołowski has obtained his PhD in the field of technical sciences at the Warsaw University of Technology. He has had many years of experience in implementing private investments in the new technologies, as well as an extensive professional experience in the health care sector. The founder of Prosper S.A. which after merging with Torfarm S.A. since 2009 has been a member of NEUCA S.A. Capital Group – the leader of the pharmaceutical distribution market in Poland. He is a member of supervisory boards of companies listed on the WSE. He has also been involved in Venture Capital funds: Inovo and Experior.

Dr. Tadeusz Wesołowski

Dr hab. Mariusz Czekala is a professor and lecturer at the WSB University in Wroclaw. He is a recognized expert in the field of quantitative disciplines i.e. money theory in time, elements of statistics and econometrics, fundamental and technical analysis, portfolio analysis, and stock quotation systems. He specializes in building econometric models for valuation of capital companies and investments. He published a number of scientific papers and monographs, including in the field of fundamental and technical analysis of financial instruments, effectiveness of investment funds and financial risk protection instruments.

Dr. hab. Mariusz Czekała

Andrzej Kierzkowski graduated from the University of Wroclaw majoring in computer science and postgraduate studies in publishing at the University of Warsaw. Publisher, IT specialist, individual investor. Co-founder and for many years a member of the Management Board of companies associated with the publishing market, including Helion S.A. and helion.pl. Has experience in building start-ups and M&A. For many years, he has managed finances of companies, especially in the first stages of development.

Andrzej Kierzkowski
Supervisory Board information

Professor Jacek Otlewski is an experienced biochemist, biophysicist and molecular biologist, a researcher of the structure and function of proteins. For many years, he has been developing phage display technology for antibodies and other protein structures. His research interests are related to targeted therapy and the development of conjugates of therapeutic proteins and cytostatics in the treatment of cancer. He supervised several dozens of doctorates, authored over 150 publications and several patents. He is a member of the Polish Academy of Sciences, European Molecular Biology Organization and Academia Europaea. Since 1994, he is the head of the Protein Engineering Department and in the years 2006-2012 he served as dean of the Faculty of Biotechnology of the University of Wroclaw.

Prof. Dr. hab. Jacek Otlewski

Dr. Waldemar Priebe is Professor of Medicinal Chemistry at the Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, in Houston (USA). His career developed in the translational space between research on novel approaches to drug design, preclinical studies, as well as industry and business. Waldemar Priebe is a cofounder of numerous companies, a few of which are in the NASDAQ index. He has also served as a consultant to numerous pharmaceutical companies. Dr. Priebe’s research focuses on metabolic pathway inhibition in cancer. Results and inventions of Dr. Priebe are published in more than 200 scientific articles and protected by over 50 patents.

Dr. Waldemar Priebe

Dr. Radosław Zagożdżon graduated from the Faculty of Medicine of the Medical University of Warsaw. He was a postdoctoral fellow and worked at Beth Israel Deaconess Medical Center of the Harvard Medical School in Boston (USA) and at University College Dublin in Ireland. Since 2017, he has been the head of the Department of Clinical Immunology at the Institute of Transplantation of the Medical University of Warsaw, at the same time working as a physician in the Department of Immunology, Transplantology and Internal Diseases of the Infant Jesus Clinical Hospital. He is also a scientific consultant in the Department of Bioinformatics at the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. Dr Zagożdżon has several years of medical and scientific experience, including conducting animal research to study the effects of new compounds on the immune system and in cancer.

Dr. hab. Radosław Zagożdżon

Professor Bogusław Paradowski is a specialist in neurology with several years of experience. He works among others in the Neurology Clinic at the University Clinical Hospital in Wrocław, where he is a deputy head of the clinic. His scientific interests encompass demyelination diseases, including multiple sclerosis, vascular diseases and dementia. Thanks to his initiative, nine medical centers were established in Lower Silesia, where patients suffering from multiple sclerosis are treated with modern I-line methods. For over 20 years, professor Paradowski has been Lower Silesian Voivodeship chief consultant in the field of neurology. Since 2017, he has held the position of associate professor at the University of Medical Sciences in Wroclaw.

Dr. hab. Bogusław Paradowski

Professor Konrad Rejdak, M.D. is a specialist in neurology. He is head of the Department and Clinic of Neurology at the Faculty of Medicine at the Medical University of Lublin, and the president-elect of the Polish Society of Neurology. Professor Rejdak is also a member of the Scientific Panel of the European Academy of Neurology, as well as numerous scientific societies, both Polish and international (including the American Academy of Neurology, International League Against Epilepsy, ECTRIMS). He is also a voivodeship consultant in the field of neurology in the Lubelskie Voivodeship.

Prof. Dr. hab. Konrad Rejdak

During its decade of operation, Pure Biologics has built a team of experts both in scientific fields – biotechnology, protein engineering, molecular biology, biophysical analysis, cell biology and antibody & aptamer discovery,
as well as from the sectors of business support and management.

A majority of our staff has international experience acquired while working in various places. Our team of specialists lies at the heart of our R&D projects, and we are certain that no challenge is insurmountable for us.

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers